تاریخچه درآمد، سود و جریان نقد از صورتهای مالی رسمی.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
نمودارهای تعاملی و صورتهای مالی کامل ← مدل ارزشگذاری (DCF) ←
| صورت سود و زیان | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| مجموع درآمد | $5.0B | $4.7B | $4.0B | $3.6B | $2.9B | $2.4B | $1.9B | $1.5B | $1.0B | $718M | $573M | $402M | $259M | $160M | $100M | $76M | $49M | $30M | $10M | $5M | $2M |
| سود ناخالص | $3.1B | $2.8B | $2.4B | $2.3B | $1.9B | $1.7B | $1.3B | $932M | $664M | $492M | $378M | $278M | $176M | $100M | $47M | $36M | $18M | $4M | ($6M) | ($8M) | ($9M) |
| حاشیه سود ناخالص % | 62.8% | 60.0% | 60.5% | 63.2% | 64.7% | 68.6% | 66.4% | 63.1% | 64.4% | 68.5% | 66.0% | 69.2% | 68.0% | 62.6% | 46.7% | 47.0% | 37.9% | 12.3% | -56.2% | -175.2% | -405.1% |
| سود عملیاتی (EBIT) | $1.1B | $912M | $600M | $598M | $391M | $266M | $300M | $142M | ($186M) | ($42M) | ($64M) | ($57M) | ($22M) | ($29M) | ($56M) | ($45M) | ($45M) | ($46M) | ($53M) | ($47M) | ($49M) |
| حاشیه سود عملیاتی % | 22.9% | 19.6% | 14.9% | 16.5% | 13.4% | 10.9% | 15.5% | 9.6% | -18.1% | -5.9% | -11.2% | -14.2% | -8.3% | -18.1% | -55.8% | -58.8% | -93.1% | -154.4% | -537.0% | -1008.8% | -2273.0% |
| سود خالص | $1.0B | $836M | $576M | $542M | $341M | $217M | $494M | $101M | ($127M) | ($50M) | ($66M) | ($58M) | ($22M) | ($30M) | ($54M) | ($45M) | ($55M) | ($54M) | ($55M) | ($46M) | ($47M) |
| حاشیه سود خالص % | 20.1% | 17.9% | 14.3% | 14.9% | 11.7% | 8.9% | 25.6% | 6.9% | -12.3% | -7.0% | -11.4% | -14.3% | -8.6% | -18.6% | -54.5% | -58.7% | -113.5% | -180.3% | -560.9% | -991.5% | -2147.6% |
| EBITDA | — | $1.4B | $946M | $917M | $565M | $378M | $377M | $213M | ($75M) | ($20M) | ($49M) | ($46M) | ($13M) | ($22M) | ($49M) | ($41M) | ($51M) | ($43M) | ($50M) | ($43M) | ($47M) |
| سود هر سهم (EPS) | $2.52 | $2.06 | $1.40 | $1.27 | $0.80 | $0.51 | $1.27 | $0.27 | $-0.36 | $-0.15 | $-0.20 | $-0.18 | $-0.07 | $-0.10 | $-0.20 | $-0.17 | $-0.24 | $-0.30 | $-0.47 | $-0.41 | $-0.43 |
| سهام منتشرشده (میلیون) | — | 406M | 413M | 426M | 428M | 429M | 390M | 369M | 353M | 345M | 334M | 319M | 301M | 284M | 275M | 262M | 228M | 177M | 118M | 113M | 109M |
منبع: گزارشهای عمومی شرکت (SEC). پیش از اتکا به هر رقم، آن را در SEC EDGAR بررسی کنید.
ترازنامهها، جریانهای نقدی، دادههای فصلی و نسبتهای مالی کامل در نمایشگر تعاملی DXCM در دسترس است. /companies/us/DXCM
اطلاعات این وبسایت صرفاً برای اهداف آموزشی و اطلاعرسانی است و توصیه سرمایهگذاری نیست. هیچ هدف قیمتی یا توصیهای منتشر نمیشود.
About TickerBase · Data methodology & sources · Privacy · Terms